Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma

International Journal of Biological Sciences

Volumn 9, Issue 3, 2013, Pages 303-312

  Ji, Junfang ^a   Yu, Lei ^a,b   Yu, Zhipeng ^a   Forgues, Marshonna ^a   Uenishi, Takahiro ^c   Kubo, Shoji ^c   Wakasa, Kenichi ^c   Zhou, Jian ^b   Fan, Jia ^b   Tang, Zhao You ^b   Fu, Shijun ^d   Zhu, Hongguang ^d   Jin, Jason Gang ^d   Sun, Hui Chuan ^b   Wang, Xin Wei ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FUDAN UNIVERSITY   (China)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d ShanghaiBio Corporation   (United States)

Author keywords

Adjuvant therapy; Companion diagnostics; Hepatocellular carcinoma; Interferon alpha; miR 26

Indexed keywords

ALPHA INTERFERON; IMMUNOLOGIC FACTOR; MICRORNA; MIRN26A MICRORNA, HUMAN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPANION DIAGNOSTICS.; FEMALE; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MIR-26; POLYMERASE CHAIN REACTION; SURVIVAL; VERY ELDERLY;

ADJUVANT THERAPY; COMPANION DIAGNOSTICS.; HEPATOCELLULAR CARCINOMA; INTERFERON-ALPHA; MIR-26;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 84875300687     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.6214     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
3. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-442.
5. Sun HC, Tang ZY, Wang L et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006;132:458-465.
6. Lo CM, Liu CL, Chan SC et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007;245:831-42.
7. Clavien PA. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg 2007;245:843-845.
8. Uenishi T, Nishiguchi S, Tanaka S, Yamamoto T, Takemura S, Kubo S. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 2008;98:358-362.
9. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
11. Ji J, Shi J, Budhu A et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009;361:1437-1447.
12. Ji J, Wang XW. Identification of Cancer Stem Cell-Related MicroRNAs in Hepatocellular Carcinoma. Methods Mol Biol 2012;826:163-175.
13. Dancey JE, Dobbin KK, Groshen S et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010;16:1745-1755.
14. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826.
15. Cronin M, Pho M, Dutta D et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004;164:35-42.
16. Budhu A, Jia HL, Forgues M et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008;47:897-907.
17. Budhu A, Forgues M, Ye QH et al. Prediction of venous metastases, recurrence and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111.
18. Ye QH, Qin LX, Forgues M et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-423.
19. Ji J, Wang XW. New kids on the block: Diagnostic and prognostic microRNAs in hepatocellular carcinoma. Cancer Biol Ther 2009;8:1686-1693.
20. Ji J, Yamashita T, Budhu A et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009;50:472-480.
21. Yamashita T, Ji J, Budhu A et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009;136:1012-1024.
22. Lee JS, Heo J, Libbrecht L et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-416.
23. Roessler S, Long EL, Budhu A et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 2012;142:957-966.
24. Budhu A, Roessler S, Zhao X et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology 2013; In press.
25. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-2096.
26. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.